About Rallybio

Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. We are focused on rapidly advancing our pipeline of promising product candidates and on further expanding our portfolio to execute on our mission.   

The Company’s lead product candidate, RLYB211, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

FNAIT is a disorder that can occur during pregnancy and is caused by an incompatibility between mother and fetus of a specific human platelet antigen (HPA), most commonly HPA-1. This incompatibility can cause a pregnant woman to develop antibodies that attack the platelets of her fetus. The destruction of platelets in the fetus can result in severe thrombocytopenia in the baby, potentially leading to intracranial hemorrhage (ICH). The consequences of ICH can be devastating, and include miscarriage of the fetus, loss of the newborn, and severe lifelong neurological disability in those babies who survive.

With RLYB211, Rallybio hopes to eradicate FNAIT resulting from HPA-1a incompatibility. RLYB211 is designed to prevent FNAIT through a mechanism known as antibody-mediated immune suppression (AMIS). There is currently no approved therapy for the prevention or treatment of FNAIT.

Beyond RLYB211, Rallybio has a pipeline of product candidates in the areas of hematology, immuno-inflammation and metabolic disease.

Headquartered in New Haven, Connecticut, with an additional location at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut, Rallybio continues to place considerable scientific resources behind the development of promising product candidates to deliver on its mission.

Rallybio Team

Founded by biopharma industry leaders with extensive research, development, and business experience, Rallybio has built a formidable team uniquely capable of effectively identifying, attaining and developing assets that are aligned with Rallybio’s mission.

Board of Directors

Helen M. Boudreau

Ms. Boudreau is a retired senior executive with a 30-year career in the biotech, pharmaceuticals, consulting and banking industries. Most recently, she served as Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute. Over the course of her career, Ms. Boudreau held positions of increasing scope and responsibility in finance in the biotech and pharmaceutical industries, including roles as Chief Financial Officer for Proteostasis Therapeutics (NASDAQ: PTI), Chief Financial Officer for FORMA Therapeutics, Chief Financial Officer for Novartis Corporation in the U.S., global Chief Financial Officer for Novartis Oncology and senior finance positions at Pfizer, Inc. She currently serves on the Board of Premier Inc. (NASDAQ: PINC), a healthcare improvement company, and three private biotechnology companies. She previously served on the board of Proteostasis Therapeutics, Inc. (NASDAQ: PTI), and was Chair of the Audit Committee. Ms. Boudreau received a BA in Economics from the University of Maryland, and an MBA from the Darden Graduate School of Business Administration, University of Virginia.

Ms. Boudreau is the Chair of the Audit Committee at Rallybio.

Rob Hopfner, RPh, PhD, MBA

Dr. Hopfner is a Managing Partner at Pivotal bioVenture Partners, where he focuses on drug discovery and development investments. He has a long track record of working successfully with entrepreneurs to progress novel, important medicines through development and onto the market. Dr. Hopfner was previously a Managing Director at Bay City Capital and prior to that worked in business development and investment roles at DuPont Pharmaceuticals and at Ag-West Biotech. He holds a PhD in Pharmacology from the University of Saskatchewan and an MBA from the University of Chicago Booth School of Business. Dr. Hopfner completed his post-doctoral work at Harvard Medical School. He started his career as a pharmacist.

Ron Hunt

Mr. Hunt is a Managing Director at New Leaf Venture Partners, and focuses on early to late stage investments in biopharmaceuticals.  He was one of the founders of New Leaf in 2005, and today has over two decades of experience investing in, and building companies focused on developing novel medicines that address important unmet medical needs.  Prior to his start in venture capital in 1998, Mr. Hunt was a strategy and operations consultant to clients in the pharmaceutical and medical device industries. His experience also includes a number of sales and marketing positions with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Mr. Hunt is a graduate of The Wharton School (MBA) and Cornell University (B.S.).

Lucian Iancovici, MD 

Dr. Iancovici is a Principal with TPG Growth based in San Francisco, where he focuses on healthcare investing. Since joining TPG, he has led investments in Sling (board member) and Rallybio (board member) and worked on Sutrovax (board observer) and Ceribell (board observer), among other investments.  Prior to joining TPG, Dr. Iancovici was a GP at dRx Capital and led the Qualcomm Life Fund. Among the investments Dr. Iancovici led or co-led were Edico Genome (acquired by Illumina) and Fitbit (IPO, FIT). Previously, he worked at McKinsey & Company in the North American healthcare practice advising on clinical- and business-model transformation for large hospital systems. Dr. Iancovici is a board-certified Internist and practiced in New York prior to joining McKinsey & Company. He trained in internal medicine at Columbia University Medical Center and completed both medical school and undergraduate studies at Tufts University.

Martin Mackay, PhD

Dr. Mackay is a co-founder of Rallybio, and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca and Alexion.  He obtained a First Class Honours Degree in microbiology from Heriot-Watt University and his PhD in molecular genetics from the University of Edinburgh. Dr. Mackay is currently a member of the Board of Directors of Charles River Laboratories and Novo Nordisk, and is a Senior Advisor at New Leaf Ventures.

Kush M. Parmar, MD PhD

Dr. Parmar is a Managing Partner at 5AM Ventures. He serves as a Director on the Boards of Akouos, Entrada, Homology (NASDAQ: FIXX), and Vor Biopharma. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and served as Board Member or Observer for Achaogen (NASDAQ: AKAO), Arvinas (NASDAQ: ARVN), Audentes (NASDAQ: BOLD), Envoy (acquired by Takeda) and scPharmaceuticals (NASDAQ: SCPH). Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University and an MD from Harvard Medical School. Dr. Parmar is based in the Boston, MA office.

Timothy Shannon, MD

Dr. Shannon is a General Partner at Canaan Partners. He also serves on the boards of Canaan portfolio companies Arvinas (NASDAQ: ARVN), IDEAYA Biosciences, NextCure, and Vivace Therapeutics. Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President and head of Global Medical Development. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine. Dr. Shannon received his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University. He earned his medical degree from the University of Connecticut and has a bachelor’s in Chemistry from Amherst College.

Paula Soteropoulos

Ms. Soteropoulos has more than 30 years of rare disease biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation and company building. In addition to a strong focus on rare disease, her career spans a broad range of therapeutic areas including cardiovascular and metabolism, neurology, infectious disease, renal, and transplant and oncology. She currently serves as Executive Chairman of Ensoma and as a member of the Board of Directors of uniQure. Previously, she served as founding CEO and member of the Board of Directors of Akcea Therapeutics, a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases. Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. where she led key strategic alliances and built preclinical programs and alliances. Before Moderna, Ms. Soteropoulos spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. In this role, Ms. Soteropoulos led all aspects of the cardiovascular business from early portfolio prioritization of science and new business development opportunities through commercialization. Ms. Soteropoulos earned an executive management certificate from the University of Virginia – Darden Graduate School of Business Administration, and a Master of Science in Chemical and Biochemical Engineering and a Bachelor of Science in Chemical Engineering from Tufts University. 

Commitment to Patients

Rallybio is dedicated to developing medicines that provide a life-transforming benefit for patients with severe and rare diseases. As we advance our pipeline of transformative therapeutic candidates, we are committed to working side-by-side with rare disease communities to increase awareness and help restore the lives of the patients, families, and caregivers affected by these disorders.

Rallybio is a member of the National Organization for Rare Disorders (NORD) Corporate Council.